The pain is usually experienced under or to the left of the sternum (breastbone) and radiates to the left shoulder and down the upper arm; less frequently, it spreads to the right shoulder. The attack usually subsides without residual discomfort and, when precipitated by physical exertion, is quickly halted when the subject rests. Often the attacks are separated by weeks, months, even years in which symptoms subside. Symptoms usually begin after the age of 50, more often in men than women, and frequently follow physical exertion, excitement, eating, smoking, or exposure to cold. Associated symptoms are faintness and difficulty in breathing.
Nitrates (e.g., amyl nitrite or nitroglycerin), drugs that dilate the blood vessels of the heart, are traditionally used in treatment. Newer drug treatments include beta-blockers and calcium-channel blockers. Significant narrowing of the coronary arteries may require surgical treatment, such as a coronary artery bypass, a procedure that splices healthy blood vessels taken from elsewhere in the body to the affected coronary arteries in such a way that the clogged areas are bypassed. In angioplasty, a balloon-tipped catheter is inserted through the skin into a blood vessel and maneuvered to the clogged artery. There it is threaded into the blockage and inflated, compressing the plaque against the arterial walls. New techniques use atherotomes to mechanically cut the plaque or cold lasers to remove plaque with bursts of ultraviolet light.
Angina pectoris, commonly known as angina, is severe chest pain due to ischemia (a lack of blood and hence oxygen supply) of the heart muscle, generally due to obstruction or spasm of the coronary arteries (the heart's blood vessels). Coronary artery disease, the main cause of angina, is due to atherosclerosis of the cardiac arteries. The term derives from the Greek ankhon ("strangling") and the Latin pectus ("chest"), and can therefore be translated as "a strangling feeling in the chest".
It is not common to equate severity of angina with risk of fatal cardiac events. There is a weak relationship between severity of pain and degree of oxygen deprivation in the heart muscle (i.e. there can be severe pain with little or no risk of a heart attack, and a heart attack can occur without pain).
Worsening ("crescendo") angina attacks, sudden-onset angina at rest, and angina lasting more than 15 minutes are symptoms of unstable angina (usually grouped with similar conditions as the acute coronary syndrome). As these may herald myocardial infarction (a heart attack), they require urgent medical attention and are generally treated as a presumed heart attack.
Myocardial ischemia comes about when the myocardia (the heart muscles) receive insufficient blood and oxygen to function normally either because of increased oxygen demand by the myocardia or by decreased supply to the myocardia. This inadequate perfusion of blood and the resulting reduced delivery of oxygen and nutrients, is directly correlated to blocked or narrowed blood vessels.
A variant form of angina (Prinzmetal's angina) occurs in patients with normal coronary arteries or insignificant atherosclerosis. It is thought to be caused by spasms of the artery. It occurs more in younger women.
In patients in whom such noninvasive testing is diagnostic, a coronary angiogram is typically performed to identify the nature of the coronary lesion, and whether this would be a candidate for angioplasty, coronary artery bypass graft (CABG), treatment only with medication, or other treatments. In patients who are in hospital with unstable angina (or the newer term of "high risk acute coronary syndromes"), those with resting ischaemic ECG changes or those with raised cardiac enzymes such as troponin may undergo coronary angiography directly.
Myocardial ischemia can result from:
Atherosclerosis is the most common cause of stenosis (narrowing of the blood vessels) of the heart's arteries and, hence, angina pectoris. Some people with chest pain have normal or minimal narrowing of heart arteries; in these patients, vasospasm is a more likely cause for the pain, sometimes in the context of Prinzmetal's angina and syndrome X.
Myocardial ischemia also can be the result of factors affecting blood composition, such as reduced oxygen-carrying capacity of blood, as seen with severe anemia (low number of red blood cells), or long-term smoking.
Recently, angina was tied to exposure of Bisphenol-A among adults in the US.
Surprising perhaps is that exercise is also a very good long term treatment for angina (but only particular regimes - gentle and sustained exercise rather than dangerous intense short bursts), probably working by complex mechanisms such improving blood pressure and promoting coronary artery collateralisation.
Identifying and treating risk factors for further coronary heart disease is a priority in patients with angina. This means testing for elevated cholesterol and other fats in the blood, diabetes and hypertension (high blood pressure), encouraging stopping smoking and weight optimisation.
Ranolazine (Ranexa) is a new class of anti anginal drug that was approved by the Food and Drug Administration (FDA)
Recently, University of Cincinnati medical researchers in cardiology have tried to use a non-invasive, non-surgical collecting tool to gather harvested erythropoietic bone marrow-based adult stem cells and coax them into regrowing new coronary blood vessels to supply the cardiac muscle's cells (cardiac myocytes) with oxygenated blood, with some success- leading to larger Phase 2 trials.
The largest randomised trial of an anti-anginal drug to date is the ACTION trial. It included 7,665 patients with stable angina pectoris. ACTION demonstrated that the calcium channel blocker nifedipine (Adalat) prolongs cardiovascular event- and procedure-free survival in patients with coronary artery disease. For example new overt heart failures were reduced by 29% compared to placebo. This finding confirms the vascular-protective effects of nifedipine.
Although zinc is not currently used to treat angina pectoris, there are reports documenting its benficial effects. A report of zinc to treat angina pectoris as early in 1899 has been found. A review of the literature by Eby and Halcomb showed that: Administration of zinc sulfate was a beneficial treatment in patients with severely symptomatic, inoperable atherosclerotic disease. There was no difference in zinc concentration between patients with and without atherosclerosis in whole blood, erythocytes or hair, but there was a major difference between normal aorta and diseased aortas. Zinc was also effective in both angina pectoris and Raynaud's disease. Environmental exposure to zinc in Polish mines resulted in a 40% reduction in the incidence of angina compared with non miners. Lead had no effect while cadmium exposure resulted in more than tripling the incidence of angina of effort. There is evidence that zinc can provide antiatherogenic properties by preventing metabolic physiologic derangements of the vascular endothelium. Because of its antioxidant and cell-plasma membrane-stabilizing properties, zinc appears to be crucial for the protection against cell-destabilizing agents such as polyunsaturated lipids and inflammatory cytokines. Zinc also may be antiatherogenic by interfering with signaling pathways involved in apoptosis. Certain lipids and zinc deficiency may potentiate the cytokine-mediated inflammatory response and endothelial cell dysfunction in atherosclerosis. As people grow older, they may ingest less zinc and absorption of zinc from the diet may falter. Angina pectoris may result from zinc deficiency. The main source of zinc in the diet is meat, and patients are routinely advised to reduce their consumption of meat due to concerns about cholesterol. Reflecting a shortage of zinc in the diet, the RDA for zinc has been recently reduced. Therapeutic dosages of bioavailable zinc for angina have been reported to be 60 mg of zinc three times per day up to 300 mg per day for no longer than 2 weeks (due to the risk of inducing copper deficiency) and copper supplementation is also advised. This benefit is reminescent of magnesium treatment of varient angina.
As shown by Jenner et al., zinc supplementation did not significantly alter the increase in total plasma cholesterol levels observed in rabbits fed high cholesterol. However, in cholesterol fed rabbits zinc supplementation significantly reduced the accumulation of total cholesterol levels in aorta which was accompanied by a significant reduction in average aortic lesion cross sectional areas of the animals. Elevated levels of cholesterol oxidation products (5,6- a and b cholesterol epoxides, 7b-hydroxycholesterol, 7-ketocholesterol) in aorta and total F2-isoprostanes in plasma and aorta of rabbits fed cholesterol diet were significantly decreased by zinc supplementation. Their data indicated that zinc has an anti-atherogenic effect, possibly due to a reduction in iron-catalysed free radical reactions.